NEW YORK (GenomeWeb News) – KineMed has licensed GeneGo’s MetaCore software for an ongoing Phase II prognostic study of chronic lymphocytic leukemia, GeneGo said today.
 
KineMed is testing a biomarker of CLL flux as a predictor of disease course that is intended to stratify indolent versus aggressive disease.
 
MetaCore is GeneGo’s flagship product and is used for target selection and validation, identification of biomarkers for disease states, and toxicology.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.